伏立康唑和伊曲康唑治疗老年恶性肿瘤合并肺部真菌感染的疗效观察

The clinical observation of voriconazole and itraconazole in the treatment of elderly patients with malignant tumor and pulmonary fungal infection

目的评价伏立康唑和伊曲康唑治疗老年恶性肿瘤合并肺部真菌感染的临床疗效和安全性。方法回顾性分析60例老年恶性肿瘤合并肺部真菌感染患者的临床资料,其中29例患者采用伏立康唑注射液治疗(伏立康唑组),31例患者采用伊曲康唑注射液治疗(伊曲康唑组),比较两种治疗方式的临床有效率和不良反应。结果伏立康唑组患者的有效率和不良反应率发生率分别为82.8%和13.8%,伊曲康唑组患者的有效率和不良反应发生率分别为70.9%和25.8%,两组患者比较,差异有统计学意义(P<0.05)。结论伏立康唑治疗老年恶性肿瘤合并肺部真菌感染的临床疗效优于伊曲康唑,安全性好,值得临床进一步推广。

Objective To investigate the efficacy and safety of voriconazole and itraconazole in elderly patients with malignant tumor and pulmonary fungal infection. Methods A retrospective analysis of clinical data was conducted in 60 elderly patients with malignant tumor and pulmonary fungal infection. 29 cases received treatment of voriconazole（ voriconazole group） and 31 cases received treatment of itraconazole（ itraconazole group）. The clinical efficacy and adverse events were compared between the two groups. Results The clinical efficacy rates of voriconazole group and itraconazole group were 82. 8% and 70. 9%,respectively. The incidence of adverse events in the two groups was 13. 8% and 25. 8%,respectively. There was significant difference between the two groups in terms of clinical efficacy and adverse events（ P〈0. 05）. Conclusion Voriconazole exhibits better safety and more effective than itraconazole in treatment of elderly patients with malignant tumor and pulmonary fungal infection. It was worthy further promotion.